glp-1 receptor agonist atrial fibrillation risk Effects of Glucagon-Like Peptide-1 Agonists on Recurrence After Catheter Ablation Glucagon-like peptide 1 receptor agonists:

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide

This is the same physiologic process seen when someone stops lifting weights: muscle size decreases because the stimulus is gonenot because muscle is being destroyed. Common Misconception: GLP-1 Drugs Burn Muscle Reality: Muscle loss during GLP-1associated weight loss is driven by reduced mechanical load and insufficient protein/calories , not by a toxic or catabolic drug effect. When Lean-Mass Loss Becomes True Muscle Wasting True muscle wasting is uncommon with GLP-1 therapy and is usually related to undernutrition , not the medication itself

10.7326/ANNALS-25-00716

Can IIH be cured